U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07128641) titled 'Odronextamab in Low Tumor Volume Advanced FL' on Aug. 14.
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of treating previously untreated Follicular Lymphoma (FL) with odronextamab.
The name of the study drug in this research study is:
-Odronextamab (a type of monoclonal antibody)
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Follicular Lymphoma
Lymphoma
Intervention:
BIOLOGICAL: Odronextamab
A CD20xCD3 bispecific monoclonal antibody, glass vials, via intravenous (into the vein) infusion per protocol.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Gottfried von K...